|

A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes

RECRUITINGPhase 3Sponsored by Eli Lilly and Company
Actively Recruiting
PhasePhase 3
SponsorEli Lilly and Company
Started2025-05-15
Est. completion2027-01
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations35 sites
View on ClinicalTrials.gov →

NCT06993792

Summary

The purpose of this Master Protocol is to support two studies to see how well and how safely orforglipron works compared to placebo in participants who have obesity or overweight with or without type 2 diabetes. Participants will be screened for about 4 weeks, after which they will enroll into either J2A-MC-GZP1, NCT06972459 (do not have type 2 diabetes) or J2A-MC-GZP2, NCT06972472 (have type 2 diabetes).

Eligibility

Age: 18 Years+Healthy volunteers accepted
There are no specific eligibility criteria for the Master Protocol.

* See study GZP1 for eligibility criteria relevant to participants with obesity and overweight without type 2 diabetes
* See study GZP2 for eligibility criteria relevant to participants with type 2 diabetes

Conditions4

DiabetesObesityOverweightType 2 Diabetes

Locations35 sites

Clinical Research Institute of Arizona (CRI) - Sun City West
Sun City West, Arizona, 85375
623-293-1360
Novak Clinical Research - Tucson - North La Cholla Boulevard
Tucson, Arizona, 85741
Thili Kulatilake
Norcal Endocrinology & Internal Medicine
San Ramon, California, 94583
925-552-5280
Southern California Clinical Research
Santa Ana, California, 92701
714-474-2173
Care Access - Thousand Oaks
Thousand Oaks, California, 91360
805-778-5143

Browse More Trials

Diabetes trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.